Skip to content
value.today

Swing Therapeutics, Inc.

Total raised
$31 M
3 rounds on record
Latest round
$11 M
May 2025
First round on record
Aug 2019
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Swing Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$3 MIssued in a merger or acquisition$2 to $10 million

Swing Therapeutics, Inc.: Private sale, Aug 2025

Investors in this round

1 investor had bought by the notice of Sep 15, 2025: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Rosenbluth · Executive Officer, Director
  • Andrew Firlik · Director
  • Corey McCann · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Rosenbluth, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2025. Read the notice at the SEC.

equitySEC
May 2025$11 MNo. 3$10 to $50 million

Swing Therapeutics, Inc.: Raise no. 3, May 2025

Investors in this round

14 investors had bought by the notice of Aug 29, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $15 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Rosenbluth · Executive Officer, Director
  • Andrew Firlik · Director
  • Corey McCann · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Rosenbluth, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 29, 2025. Read the notice at the SEC.

equity, optionsSEC
Jan 2022$10 MNo. 2$10 to $50 million

Swing Therapeutics, Inc.: Raise no. 2, Jan 2022

Investors in this round

11 investors had bought by the notice of Jul 26, 2022: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $13 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Rosenbluth · Executive Officer, Director
  • Andrew Firlik · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Rosenbluth, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 26, 2022. Read the notice at the SEC.

equitySEC
Aug 2019$9 MNo. 1$2 to $10 million

Swing Therapeutics, Inc.: Raise no. 1, Aug 2019

Investors in this round

5 investors had bought by the notice of Jul 26, 2022: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael Rosenbluth · Executive Officer, Director
  • Andrew Firlik · Director
  • Zack Lynch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Rosenbluth, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 26, 2022. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Swing Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2025

That is all the official record says: Swing Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Swing Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Swing Therapeutics, Inc.
NameRoleNamed in
Michael RosenbluthExecutive officerSep 2025
Andrew FirlikDirectorSep 2025
Corey McCannDirectorSep 2025
Michael RosenbluthDirectorSep 2025
Zack LynchDirectorSep 2025